Fazpilodemab

N/A

Report date: 2024/12/13 20:00:39

Base Information

Drug NameFazpilodemab

Drug Alias NameRG-7992BFKB-8488ARO-7040551

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-FGFR1Anti-Klotho beta

TargetsKlotho betaFibroblast growth factor receptor 1

Therapy Area/IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A